Rituximab and Plasmapheresis for Post-transplant Recurrence of FSGS.
- Author:
Ju Yeon NAM
1
;
An Sook CHOI
;
Su Jin KIM
;
Byoung Hoon JI
;
Joon Suk OH
;
Young Ki SON
;
Yong Hun SIN
;
Joong Kyung KIM
;
Yong Jin KIM
Author Information
1. Division of Nephrology, Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea. dudrlek@medigate.net
- Publication Type:Case Report
- Keywords:
Focal segmental glomerulosclerosis;
Rituximab;
Kidney transplantation
- MeSH:
Adolescent;
Antibodies, Monoclonal, Murine-Derived;
Biopsy;
Glomerulosclerosis, Focal Segmental;
Humans;
Kidney;
Kidney Diseases;
Kidney Transplantation;
Living Donors;
Plasmapheresis;
Proteinuria;
Recurrence;
Sclerosis;
Transplantation, Homologous;
Transplants;
Rituximab
- From:Korean Journal of Nephrology
2010;29(2):292-295
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Focal segmental glomerular sclerosis (FSGS) is known to recur in 20-40% of the renal allografts with graft loss in about half of these cases. We report a successful treatment of a recurrent FSGS after kidney transplantation with rituximab and plasmapheresis. An 16-year-old patient whose primary kidney disease was FSGS developed recurrence of proteinuria after living donor kidney transplantation despite preemptive plasmapheresis and one dose of rituximab (375 mg/m2). After kidney transplantation, nephrotic range proteinuria was detected. Kidney biopsy was done and showed recurrent FSGS. She undergone 11 times of plasmapheresis in the first 4 week post transplantation. In addition, she received additional one dose of rituximab (375 mg/m2) on day 14. Proteinuria was decreased below nephrotic range at 37 day. Ten months later, proteinuria was at 30 mg/day with excellent graft function. No significant adverse events related to rituximab or plasmapheresis were observed. Rituximab with plasmapheresis may be another option for recurrent FSGS after kidney transplantation.
